Neuphoria Therapeutics Inc.

For the period ended Jun 30, 2025. Filed Sep 29, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Sep 29, 2025

NEUP$2.76-0.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Changes in Shareholders' Equity

Consolidated Statement of Changes in Shareholders' Equity

Stock · Additional · AccumulatedOther · Total
Common Shares · Subscription · Paid-In · Comprehensive · Accumulated · Shareholders'
Shares · Amount · Receivable · Capital · Loss · Deficit · Equity
Balance at June 30, 2023	679,970	$7	$	-	$187,554,244	$(3,058,783)	$(162,484,905)	$22,010,563
Issuance of ADS shares and pre-funded ADS warrant, net of issuance costs of $1.3 million	423,984	4		-	10,111,975	-	-	10,111,979
Share-based compensation	-	-		-	814,808	-	-	814,808
Other comprehensive income	-	-		-	-	45,188	-	45,188
Net loss	-	-		-	-	-	(15,492,166)	(15,492,166)
Balance at June 30, 2024	1,103,954	$11	$	-	$198,481,027	$(3,013,595)	$(177,977,071)	$17,490,372
Exercise of pre-funded ADS warrant	524,705	5		-	624	-	-	629
Issuance of common stock in connection with our ATM facility, net of offering costs of $0.1 million and stock subscription receivable	349,801	3		(94,685)	1,962,485	-	-	1,867,803
Share issue costs	-	-		-	(339,524)	-	-	(339,524)
Share-based compensation	-	-		-	184,397	-	-	184,397
Other comprehensive income	-	-		-	-	168,529	-	168,529
Net loss	-	-		-	-	-	(369,632)	(369,632)
Balance at June 30, 2025	1,978,460	$19		$(94,685)	$200,289,009	$(2,845,066)	$(178,346,703)	$19,002,574

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.